HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

(2011) J. A. Sparano et al.   CLINICAL CANCER RESEARCH

Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy

(2011) Chun Hing Tse et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

(2011) Edith A. Perez et al.   JNCI-Journal of the National Cancer Institute

Subtype and pathway specific responses to anticancer compounds in breast cancer

(2011) L. M. Heiser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GRB7 protein over-expression and clinical outcome in breast cancer

(2010) Betsy Ramsey et al.   BREAST CANCER RESEARCH AND TREATMENT

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

(2010) Allan Lipton et al.   CANCER

17q12-21 – The pursuit of targeted therapy in breast cancer

(2010) R.W. Glynn et al.   CANCER TREATMENT REVIEWS

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer

(2009) Y. Nadler et al.   ANNALS OF ONCOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

(2008) M. F. Press et al.   CLINICAL CANCER RESEARCH

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY